Nuveen
BDTX icon

Nuveen’s Black Diamond Therapeutics BDTX Stock Holding History

Nuveen’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
+64,801
New +$159K ﹤0.01% 3702
2025
Q2 		– Sell
-135,587
Closed -$3.33M – 3286
2025
Q1 		$3.33M Sell
135,587
-65,948
-33% -$138K ﹤0.01% 2127
2024
Q4 		$431K Buy
201,535
+22,802
+13% +$65.3K ﹤0.01% 3031
2024
Q3 		$777K Buy
178,733
+56,730
+46% +$309K ﹤0.01% 2860
2024
Q2 		$569K Buy
+122,003
New +$655K ﹤0.01% 2943
2022
Q2 		– Sell
-86,043
Closed -$268K – 3260
2022
Q1 		$268K Buy
86,043
+1,996
+2% +$7.29K ﹤0.01% 3141
2021
Q4 		$419K Sell
84,047
-7,830
-9% -$54.7K ﹤0.01% 3114
2021
Q3 		$873K Buy
91,877
+1,230
+1% +$12.1K ﹤0.01% 3035
2021
Q2 		$1.1M Buy
90,647
+27,696
+44% +$548K ﹤0.01% 2972
2021
Q1 		$1.53M Sell
62,951
-441
-0.7% -$11.9K ﹤0.01% 2734
2020
Q4 		$2.03M Sell
63,392
-2,145
-3% -$70.5K ﹤0.01% 2502
2020
Q3 		$1.98M Buy
65,537
+16,426
+33% +$500K ﹤0.01% 2394
2020
Q2 		$2.07M Buy
49,111
+13,047
+36% +$480K ﹤0.01% 2326
2020
Q1 		$900K Buy
+36,064
New +$1.1M ﹤0.01% 2557

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Nuveen's BDTX Position: Q2 2026 in Review

Nuveen opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 64,801 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #3702 among its holdings. This is a return to the name: Nuveen previously reported a position in BDTX as recently as Q1 2025.

Nuveen first reported a position in BDTX in Q1 2020 and has held it in 14 quarters since. The position peaked at $3.33M in Q1 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Nuveen held 64,801 shares of Black Diamond Therapeutics worth $120K as of Q2 2026.
  • Black Diamond Therapeutics was a new Nuveen position in Q2 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3702 holding.
  • Nuveen first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • Nuveen's Black Diamond Therapeutics position peaked at $3.33M in Q1 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.